The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial-Reference-Cited by-同舟云学术

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Published:2013-08 Issue:9 Volume:14 Page:882-892
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sandhu Shahneen K,Schelman William R,Wilding George,Moreno Victor,Baird Richard D,Miranda Susana,Hylands Lucy,Riisnaes Ruth,Forster Martin,Omlin Aurelius,Kreischer Nathan,Thway Khin,Gevensleben Heidrun,Sun Linda,Loughney John,Chatterjee Manash,Toniatti Carlo,Carpenter Christopher L,Iannone Robert,Kaye Stan B,de Bono Johann S,Wenham Robert M

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic;Yap;CA Cancer J Clin,2011

2. The DNA damage response and cancer therapy;Lord;Nature,2012

3. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial;Audeh;Lancet,2010

4. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers;Fong;N Engl J Med,2009

5. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval;Fong;J Clin Oncol,2010

Cited by 482 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

2. Strategies for the prevention or reversal of PARP inhibitor resistance;Expert Review of Anticancer Therapy;2024-08-20

3. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer;Clinical Therapeutics;2024-08

4. Dose Optimization of Targeted Therapies for Oncologic Indications;Cancers;2024-06-09

5. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation;Frontiers in Oncology;2024-05-14